Medeon Biodesign Cash Flow Conversion Efficiency
Medeon Biodesign cash flow conversion efficiency. Based on the latest financial reports, Medeon Biodesign (6499) has a cash flow conversion efficiency ratio of -0.074x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-93.35 Million ≈ $-2.94 Million USD) by net assets (NT$1.27 Billion ≈ $39.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medeon Biodesign (2017–2025)
Cash flow conversion efficiency of Medeon Biodesign from 2017 to 2025. This chart illustrates how Medeon Biodesign's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Medeon Biodesign (6499) share price today for real-time trading data and today's change.
Medeon Biodesign Cash Flow Conversion Ratio Explained
Medeon Biodesign cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medeon Biodesign Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medeon Biodesign ranked by their cash flow conversion efficiency. Also see how much is Medeon Biodesign worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Junee Limited Ordinary Shares
NASDAQ:JUNE
|
-0.059x |
|
Computer Modelling Group Ltd.
TO:CMG
|
-0.053x |
|
Polyram Plastic Industries Ltd
TA:POLP
|
0.071x |
|
RGC Resources Inc
NASDAQ:RGCO
|
0.048x |
|
Tong Ming Enterprise Co Ltd
TW:5538
|
-0.036x |
|
AC Immune Ltd
NASDAQ:ACIU
|
-0.522x |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
-0.058x |
|
BCEG Environmental Remediation Co. Ltd.
SHE:300958
|
N/A |
Annual Cash Flow Conversion Efficiency for Medeon Biodesign (2017–2025)
The table below shows the annual cash flow conversion efficiency of Medeon Biodesign from 2017 to 2025. Review cash generation quality of Medeon Biodesign to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.54 Billion ≈ $48.42 Million |
NT$-629.14 Million ≈ $-19.82 Million |
-0.409x | +24.49% |
| 2024-12-31 | NT$1.54 Billion ≈ $48.39 Million |
NT$-832.66 Million ≈ $-26.23 Million |
-0.542x | -70.27% |
| 2023-12-31 | NT$2.37 Billion ≈ $74.72 Million |
NT$-755.08 Million ≈ $-23.79 Million |
-0.318x | -152.84% |
| 2022-12-31 | NT$3.66 Billion ≈ $115.42 Million |
NT$-461.34 Million ≈ $-14.53 Million |
-0.126x | -79.78% |
| 2021-12-31 | NT$4.19 Billion ≈ $131.96 Million |
NT$-293.38 Million ≈ $-9.24 Million |
-0.070x | -22.59% |
| 2020-12-31 | NT$2.65 Billion ≈ $83.41 Million |
NT$-151.27 Million ≈ $-4.77 Million |
-0.057x | +46.90% |
| 2019-12-31 | NT$2.25 Billion ≈ $70.85 Million |
NT$-241.99 Million ≈ $-7.62 Million |
-0.108x | -160.10% |
| 2018-12-31 | NT$1.80 Billion ≈ $56.66 Million |
NT$322.05 Million ≈ $10.15 Million |
0.179x | +188.32% |
| 2017-12-31 | NT$1.53 Billion ≈ $48.29 Million |
NT$-310.76 Million ≈ $-9.79 Million |
-0.203x | -- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more